As a transcriptional target of NRF2, upregulated NQO1 can be attenuated by NRF2 blockade to sensitize lung cancer cells to several conventional chemotherapeutic drugs including etoposide, doxorubicin and cisplatin (Wang et al., 2008a). Here, NFE2L2 is linked to lung carcinoma.